ICML 2023 | Health-related quality of life with zanubrutinib versus ibrutinib for patients with R/R CLL
Barbara Eichhorst, MD, University of Cologne, Cologne, Germany, shares some insights into patient-reported health-related quality of life (HRQOL) with the use of zanubrutinib versus ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Eichhorst discusses the EORTC-QLQ-C30 questionnaire used in this study and further highlights the results obtained. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
At the ICML meeting here as well as at EHA we present a poster with respect to the health related quality of life using the EORTC-QLQ-C30 questionnaire, comparing that in the zanubrutinib arm versus the ibrutinib arm within the ALPINE study. EORTC-QLQ-C30 has several scales which are shown and there are five functional scales and several symptom scales, and also global health status, which is assessed by several questions and patients...
At the ICML meeting here as well as at EHA we present a poster with respect to the health related quality of life using the EORTC-QLQ-C30 questionnaire, comparing that in the zanubrutinib arm versus the ibrutinib arm within the ALPINE study. EORTC-QLQ-C30 has several scales which are shown and there are five functional scales and several symptom scales, and also global health status, which is assessed by several questions and patients. And the results show actually for both arms improvement during treatment, which is what patients tell you when they finally receive treatment of their CLL and there is a little bit better recovery within the zanubrutinib arm, but it’s statistically not significant. And so overall, what these data show that quality of life in CLL patients improves if there is one BTK inhibitor better than the other one with respect to quality of life, it’s not yet clear. But CLL, with respect to the median age of the patients is definitely a difficult field because these are elderly people and they usually have also several other health problems.
Read more...
